Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have been given a consensus rating of “Buy” by the fifteen analysts that are presently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $51.72.

IART has been the subject of several analyst reports. Zacks Investment Research cut Integra LifeSciences Holdings Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, June 28th. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price objective on shares of Integra LifeSciences Holdings Corporation in a report on Monday, July 10th. BidaskClub cut Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Jefferies Group LLC raised their price objective on Integra LifeSciences Holdings Corporation from $52.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, May 31st. Finally, Oppenheimer Holdings, Inc. set a $54.00 price objective on Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a report on Monday, May 15th.

In other news, Director Donald E. Morel, Jr. bought 2,500 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The stock was acquired at an average cost of $49.29 per share, for a total transaction of $123,225.00. Following the purchase, the director now owns 29,612 shares of the company’s stock, valued at approximately $1,459,575.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Barbara B. Hill bought 5,050 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was purchased at an average price of $49.33 per share, with a total value of $249,116.50. Following the completion of the purchase, the director now directly owns 44,772 shares in the company, valued at approximately $2,208,602.76. The disclosure for this purchase can be found here. Insiders purchased a total of 17,550 shares of company stock valued at $864,842 over the last quarter. 21.50% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of IART. LS Investment Advisors LLC lifted its position in Integra LifeSciences Holdings Corporation by 90.7% during the first quarter. LS Investment Advisors LLC now owns 2,412 shares of the life sciences company’s stock worth $102,000 after acquiring an additional 1,147 shares during the last quarter. Acrospire Investment Management LLC lifted its position in Integra LifeSciences Holdings Corporation by 280.0% during the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock worth $104,000 after acquiring an additional 1,400 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Integra LifeSciences Holdings Corporation by 223.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock worth $107,000 after acquiring an additional 1,751 shares during the last quarter. First Manhattan Co. acquired a new stake in Integra LifeSciences Holdings Corporation during the first quarter worth approximately $117,000. Finally, Turner Investments LLC acquired a new stake in Integra LifeSciences Holdings Corporation during the first quarter worth approximately $126,000. Institutional investors and hedge funds own 85.28% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/10/integra-lifesciences-holdings-corporation-iart-given-average-rating-of-buy-by-brokerages.html.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded up 0.50% during mid-day trading on Tuesday, reaching $52.14. The company had a trading volume of 517,070 shares. Integra LifeSciences Holdings Corporation has a 12 month low of $37.71 and a 12 month high of $56.42. The stock has a market cap of $4.07 billion, a PE ratio of 63.59 and a beta of 0.73. The firm’s 50-day moving average price is $50.52 and its 200-day moving average price is $48.03.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.45. The firm had revenue of $282.16 million during the quarter, compared to analysts’ expectations of $283.58 million. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The company’s revenue was up 13.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.40 EPS. Equities research analysts forecast that Integra LifeSciences Holdings Corporation will post $1.90 EPS for the current fiscal year.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Stock Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related stocks with our FREE daily email newsletter.